Full-Time

Senior Scientist I

Cell Line Development

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$96.5k - $183.5k/yr

+ Short-term Incentive

San Bruno, CA, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Cell Biology
Biochemistry

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Senior Scientist I: BS with a minimum of 10 years, or MS with a minimum of 8 years of experience, or PhD with no minimum years’ experience, in molecular biology, cell biology, biochemistry, or a related discipline.
  • Demonstrated ability to read the literature, review external sources, and gather inputs to synthesize technically sound ideas and design proper experimental controls.
  • Demonstrated ability to independently analyze experimental data, draw appropriate conclusions, and communicate them to a wide audience.
  • Demonstrated proficiency with designing and implementing vector improvements to increase recombinant antibody expression levels in stable CHO cells.
  • Demonstrated theoretical command of mammalian protein expression — able to speak substantively to topics such as genomic and epigenetic regulation (e.g., genomic loci, chromatin accessibility, and DNA methylation), transcriptional and translational control, the cellular machinery of protein secretion, and mRNA stability.
  • Proficiency with Geneious Prime or similar software for designing and annotating DNA vectors, primers, and probes, and performing sequence alignments.
  • Proficiency with cell engineering to knock in / knock out target genes using CRISPR/Cas or other suitable tools.
  • Proficiency with transfection, aseptic mammalian cell culture, Octet, ViCell, CloneSelect Imager, and microfluidic clone-screening platforms such as the Beacon.
  • Demonstrated ability to learn, understand, and master new experimental techniques, and to multi-task and work within timelines.
  • Strong scientific communication skills — verbal, written, and data presentation — with detailed daily digital lab notebook record-keeping proficiency.
  • A candidate who combines hands-on wet-lab depth with the ability to think alongside the team and then execute independently.
Responsibilities
  • Independently conceive ideas and designs to investigate CHO expression technical improvements across both vector and host cell.
  • Design and test dozens of vector constructs in recombinant stable CHO cell lines for increased mAb titer.
  • Employ a variety of hands-on laboratory techniques, including transfection, aseptic CHO cell culture, DNA gene copy number analysis, RNA expression analysis, mAb titer measurement, cell engineering to knock in/out target genes, and in vitro transcription.
  • Receive externally sourced vector libraries and rapidly execute the associated transfection, screening, and clone-characterization studies to generate decision-quality data.
  • Operate and interpret data from core CLD instrumentation, including Octet (BLI titer), ViCell, CloneSelect Imager, microfluidic clone-screening platforms such as the Beacon, flow cytometry, and ddPCR / RT-qPCR copy-number and expression assays. Share responsibility for equipment maintenance.
  • Apply a rigorous theoretical and practical understanding of recombinant protein expression from the genome to the protein — including genomic loci, epigenetics, transcription, mRNA stability, translation, the organelles and secretory machinery involved, and the engineering constraints specific to industrial CHO cell line development.
  • Author and co-author cell line development technical reports and present data to the group and to leadership; contribute scientific insight to project teams.
  • Collaborate closely with cell culture, analytical, purification, and bioinformatics colleagues to meet project timelines, and adhere to corporate standards for code of conduct, safety, materials handling, and good documentation practices.
Desired Qualifications
  • While we welcome all candidates with a genuine passion for CHO expression, we strongly prefer those who bring hands-on, industry cell line development experience in a CMC / drug-substance environment over candidates with purely academic or cell-culture-development-only backgrounds.
  • Candidates with substantial experience developing CHO expression platform improvements in an industrial/CMC setting.
  • Possess a demonstrated and genuine passion for getting the most mAb titer out of recombinant CHO cells.
  • Possess a thorough understanding of the genetic and epigenetic factors governing mAb expression in recombinant stable CHO cells.
  • Previous experience working in CMC (Chemistry, Manufacturing and Controls) to contribute to the generation of recombinant CHO cell lines that will be used in GMP manufacturing.
  • Previous experience performing cellular analyses using flow cytometry.
  • Experience across multiple expression-engineering strategies beyond DNA copy number and well-known promoters.
  • Working knowledge of next-generation sequencing (NGS) for genomic DNA and RNA expression analysis — at minimum, the ability to match the appropriate NGS assay to the scientific question, and ideally hands-on experience with wet-lab library preparation and the associated data analysis and interpretation.
  • Programming and data-science skills (e.g., Python, R) for analysis and visualization of cell line development data.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.